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Background: Pregabalin is used in the treatment of postherpetic neuralgia, diabetic neuropathic pain, partial
seizures, anxiety disorders and fibromyalgia. Recognized adverse effects associated with its use include cognitive
impairment, somnolence and dizziness. Heart failure associated with pregabalin has been described, however the
strength of this association has not been well characterized. To examine this further, we will conduct a systematic
review of the risk of heart failure and edema associated with use of pregabalin.
Methods/design: We will include all studies (experimental, quasi-experimental, observational, case series/reports,
drug regulatory reports) that examine the use of pregabalin compared to placebo, gabapentin or conventional
care. Our primary outcome is heart failure and the secondary outcomes include edema and weight gain. We will
search electronic databases (MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials), and grey literature
sources (trial registries, conference abstracts) to identify relevant studies. To ensure literature saturation, we will
contact drug manufacturers, conduct forward citation searching, and scan the reference lists of key articles and
included studies. We will not restrict inclusion by language or publication status.
Two reviewers will screen citations (titles and abstracts) and full-text articles, conduct data abstraction, and appraise
risk of bias. Random-effects meta-analysis will be conducted if the studies are deemed heterogeneous in terms of
clinical, statistical and methodological factors but still suitable for meta-analysis.
Conclusions: The results of this review will assist physicians to better appreciate pregabalin’s risk for edema or
congestive heart failure and will be pertinent to the thousands of patients worldwide who are administered this
medication.
Our protocol was registered in the PROSPERO database (CRD42012002948).
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Pregabalin, a structural analogue to gamma-aminobutyric
acid (GABA), is a new medication that is widely prescribed
for chronic pain syndromes such as postherpetic neuralgia
and diabetic neuropathic pain, as well as partial seizures,
anxiety disorders and fibromyalgia [1]. It is a calcium
channel antagonist that decreases the release of several
neurotransmitters including substance P, norepinephrine
and glutamate, without binding to GABA receptors;* Correspondence: jm.ho@mail.utoronto.ca
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reproduction in any medium, provided the orhowever, its mechanism of action is still not well under-
stood [1].
Pregabalin’s known adverse effects include cognitive
impairment, somnolence and dizziness [2]. Post-
marketing surveillance has also noted an increasing
number of reports of heart failure in patients using the
drug, an adverse outcome that has not been found with
the less potent calcium channel antagonist gabapentin
[3-6]. A systematic review of randomized controlled tri-
als involving pregabalin found a 4-fold increased inci-
dence of peripheral edema, which may be associated
with heart failure. Since these trials included patients
who were healthier and more closely monitored than
the general population, this risk of edema or heart failure
may actually be higher [7]. Furthermore, individuals for
whom pregabalin is often prescribed, such as diabeticThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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known risk factors for heart failure [8]. In clinical practice,
the high background incidence of edema and heart failure
may reduce the likelihood that health care providers attri-
bute these problems to a medication.
The risks associated with pregabalin may be better stud-
ied by examining observational studies, which include
greater numbers of patients with comorbid conditions –
studies not included in previous reviews [7]. We hypo-
thesize that there is an increased risk of heart failure or
edema in individuals receiving pregabalin compared to
placebo or gabapentin. To investigate this further, we will
conduct a systematic review of pregabalin across all avail-
able studies. Our research question is “what is the risk of
heart failure or edema among patients newly started on
pregabalin compared to gabapentin, placebo or conven-
tional care?”Methods
This research protocol was developed by our team with
expertise in geriatric medicine, clinical pharmacology,
systematic review methodology, statistics and library sci-
ence. Our protocol was registered in the PROSPERO
database (CRD42012002948).
Eligibility criteria
We will include any study report that examines congestive
heart failure, edema or weight gain among adult patients
(age ≥18 years) newly prescribed pregabalin compared to
gabapentin, placebo or standard medical care. Studies will
be included regardless of publication status or language of
dissemination. We will exclude qualitative studies but all
other study designs will be included. The PICOST criteria
are as follows:
Patients – Adults ≥18 years
Intervention – Pregabalin (any dosage and duration
of use)
Comparator – Gabapentin (another calcium channel
antagonist) placebo or conventional medical care
Outcome – Heart failure (primary) edema weight gain
alone or with edema (secondary)
Studies – Clinical trials (randomized clinical trials,
quasi-randomized clinical trials, controlled clinical trials),
quasi-experimental studies (controlled before-after
studies and interrupted time series), observational
studies (case–control, cohort, case-crossover, case-time-
control), case series/reports, safety bulletins and primary
surveillance data from drug regulatory agencies
Time – No restrictions will be imposed based upon
study duration
Other – No other restrictions will be imposed (e.g.,
language publication status or year of dissemination)Information sources
An experienced librarian (LP) will conduct the literature
search and the search strategy will be peer reviewed by an-
other librarian using the Peer Review of Electronic Search
Strategies (PRESS) checklist [9]. We will search the follow-
ing electronic databases from inception onwards: Medline
(1946 to present), EMBASE (1947 to present), Cochrane
Central Register of Controlled Trials (CENTRAL). The
full search strategy for the main electronic search in
MEDLINE is presented in Appendix A. We will use the
World Health Organization International Clinical Trials
Registry Platform search portal of trial protocols to simul-
taneously search multiple trial registry sites (http://www.
controlled-trials.com/mrct/) and conference abstracts (e.g.,
American Academy of Pain Medicine annual meeting,
American Pain Society annual meeting, International
Congress for Neuropathic Pain, American Academy of
Neurology annual meeting, American Diabetes Association
annual meeting, Canadian Diabetes Association annual
meeting) for difficult to locate or unpublished (i.e., grey)
literature. The following Regulatory Authority safety
alerts will be searched: Food and Drug Administration
MedWatch (United States), European Medicines Evaluation
Agency's European Public Assessment Reports, Medicines
and Healthcare Products Regulatory Agency (United
Kingdom), Australia Adverse Drug Reactions Bulletin,
Health Canada MedEffect and the Canadian Adverse Drug
Information System. We will also search the World Health
Organization Uppsala Monitoring Centre.
Study selection
The eligibility criteria will be pilot-tested on a random
sample of 50 citations, which will be screened by the en-
tire team. A kappa statistic will be calculated to measure
inter-rater reliability and screening will only commence
when ≥60% agreement is achieved [10]. Using the online
SysRev Tool (proprietary software available at the Li Ka
Shing Knowledge Institute of St. Michael’s Hospital),
two reviewers will subsequently screen the literature
search results at citation (titles and abstracts) and full-
text article levels in duplicate. Conflicts will be resolved
by discussion between the reviewers or with a third re-
viewer, if necessary.
Some of the included study reports might be studies
examining pregabalin among the same patient popula-
tion (i.e., companion reports). To identify studies that
generate multiple reports (duplication bias), we will
record the authors' names, study location and setting,
dose and frequency of pregabalin administration (inter-
vention), number of participants and their baseline demo-
graphic data, and date and duration of the study. Once
identified, we will link these reports. We will consider the
report with the longest duration of follow-up or primary
outcome of interest as the major publication and the rest
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supplementary information.
This is a systematic review of adverse events, which
are often underreported in randomized clinical trials
[11]. To ensure that trials not reporting this information
are not systematically different compared to those that do
(i.e., outcome reporting bias [12]), we will contact authors
of trials that do not report our outcomes of interest. We
will exclude non-randomized studies that do not provide
data on our primary or secondary outcome.
Data collection process
A data abstraction form will be developed and amended
following a pilot-test on a 5% random sample of the in-
cluded studies by all reviewers. Two reviewers will sub-
sequently perform all data abstraction in duplicate.
Conflicts will be resolved by discussion or, if necessary, a
third reviewer will be involved. We will attempt to contact
study authors to verify data, as necessary. The anticipated
data that will be collected are included in Appendix B.
Risk of bias
For randomized clinical trials, we will use the Cochrane
Collaboration's 5.1.0 risk of bias tool. This 7-item tool
assesses for selection bias, performance bias, detection
bias, attrition bias, and reporting bias [13].
For non-randomized studies and observational studies, a
single risk of bias tool has not been validated [14]. As
such, we will use a combination of the Newcastle-Ottawa
Scale, the Effective Practice and Organization of Care Risk
of Bias Tool and the McMaster Quality Assessment Scale
for Harms [15-17]. We will apply the Naranjo Probability
Scale for case reports/series [15-19].
Confounding variables
The following are variables that are confounders for
pregabalin and the risk for edema or heart failure:
1. Demographics: Age, gender, sociodemographic
status/income
2. Comorbidities: Diabetes, hypertension, dyslipidemia,
congestive heart failure, cardiovascular disease,
cerebrovascular disease, renal disease, seizure
disorder, number of medications per year, burden of
illness scales (Charlson, Romano, Aggregated
Diagnosis Groups, recent hospitalization in the past
12 months)
3. Medications that affect fluid balance: Loop diuretics
4. Cardiovascular medications: Renin-angiotensin
antagonists (angiotensin converting enzyme
inhibitors, angiotensin receptor blockers, aliskiren),
negative chronotropes (beta blockers, calcium
channel blockers, digoxin), statins, antiarrhythmics,
antiplatelet agents, anticoagulants5. Medications that can exacerbate or trigger
congestive heart failure: Non-steroidal anti-
inflammatory drugs, steroids, thiazolidinediones
6. Medications associated with severe neuropathic
pain: Opioids
7. Medications associated with other indications for
pregabalin: Anticonvulsants, benzodiazepines,
antidepressants
We will record which studies adjusted for which vari-
ables, and their crude and adjusted measures of effect
size (e.g., odds ratio, relative risk).
Synthesis of results
Study heterogeneity will be examined using Q- and
I2-statistics [20]. If the studies are clinically, statistically
and methodologically homogenous, a meta-analysis will
be conducted separately for randomized clinical trials and
cohort studies using a random-effects model [21]. The
relative risk will be calculated for the occurrence of heart
failure, edema and weight gain (alone or with edema) from
randomized clinical trials, while odds ratios will be calcu-
lated for these outcomes from cohort studies. Further-
more, a network meta-analysis may be considered with
randomized clinical trials that compare pregabalin or
gabapentin with placebo. If at least 10 studies are included
in the meta-analysis, publication bias will be assessed
using a funnel plot [22]. Extensive heterogeneity, defined
as I2 >60%, will be addressed with sub-group analysis or,
if there are >10 studies reporting relevant outcomes,
meta-regression will be considered. Variables that will
be examined further using sub-group analysis and/or
meta-regression include pregabalin dose, patient age
and history of postherpetic neuralgia and of diabetic
neuropathy. The methodological quality and risk of bias
results will be scrutinized and sub-group analysis will
be conducted on those items that are of low methodo-
logical quality for the cohort studies or high risk of bias
for the randomized clinical trials. The results of case
series, case reports, and case–control studies will be sum-
marized descriptively and will not be meta-analyzed.
Discussion
Through this systematic review, we will gain a better ap-
preciation of pregabalin’s risk of heart failure and edema.
The results of this review will be of interest to clinicians
and the thousands of patients worldwide who are ad-
ministered this heavily marketed medication. Given that
pregabalin is not universally covered by health care plans
in North America, this systematic review may also be
helpful to health policy makers should they consider in-
cluding this medication in drug benefit programs.
Our knowledge exchange strategies include a publi-
cation in a peer-reviewed journal and presentations at
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Effectiveness Network meeting in Canada.
Finally, this is the first phase of a more comprehensive
network meta-analysis of the comparative harms of non-
opioid analgesics, a clinically relevant topic to clinicians,
patients and health policy makers.
Appendix A
Search strategy
Medline (1946 to present):









9. 148553-50-8.rn. [CAS Registry Number]
10. "3 isobutyl 4 aminobutyricacid".tw.
11. "3 isobutylgaba".tw.
12. "4 amino 3 isobutylbutyric acid".tw.
13. "pd 144723".tw.
14. or/1-13





20. 14 and 19
21. exp Animals/ not (exp Animals/ and Humans/)
[ removing animal studies ]
22. 20 not 21
Appendix B
Data collection
The following data categories will be collected:
1. Patient characteristics:
1. Total number (baseline, study end)
2. Setting
3. Diagnostic criteria
4. Age (median, interquartile range)





10. Date of study
2. Study characteristics:
1. Report ID (created by review author)
2. Citation and contact details3. Confirm eligibility for review
4. Reason for exclusion
5. Study design
6. Country
7. Setting (outpatient, inpatient)
8. Publication status
9. Intervention and comparator descriptions
(dosage, intensity, frequency)
10. Allocation to groups (concealed randomization,
quasi-randomization, time differences, location
differences, policy/public health decisions, cluster/
individual preferences)
11. Prospective (Whole vs. components)
12. Duration of intervention and follow-up
13. Outcomes examined
14. Variables that were assessed between groups
(potential confounders, baseline assessment of
outcome variables)
15. Funding source
16. Key conclusions of the study authors
17. Miscellaneous comments from study authors
3. Quality/Risk of bias:
1. Cochrane 5.1 collaboration's tool for assessing
risk of bias categories (randomized clinical trials)
2. Newcastle-Ottawa Scale for assessing risk of bias
categories (cohort and case–control studies)
3. Effective Practice and Organization of Care
(EPOC) for assessing risk of bias (controlled
clinical trials, controlled before-after trials and
interrupted time series)
4. Naranjo Adverse Drug Reporting Probability
Scale (case reports/series)
5. McMaster Quality Assessment Scale for Harms
Study (McHarm)
4. Adverse events (systematic review primary outcome –
congestive heart failure; secondary outcomes – edema,
weight gain)
1. Diagnostic criteria




5. Relative risk (randomized trials)
6. Odds ratio (cohort studies)
7. Severity
8. Resulted in withdrawals
9. Collected at follow-up (frequency of follow-up)
10. Collected by patient diary or checklist or
spontaneous reporting
11. Early vs. late withdrawal
12. Other adverse events reportedCompeting interests
The authors declare that they have no conflicts of interest.
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